



Corrigendum: Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction

Liyun Zhang, Juan Chen, Lianhua Yan, Qin He, Han Xie and Manhua Chen*

Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Keywords: resveratrol, heart failure with preserved ejection fraction, inflammation, macrophage polarization, oxidative stress

A Corrigendum on

Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction

by Zhang, L., Chen, J., Yan, L., He, Q., Xie, H., and Chen, M. (2021). *Front. Pharmacol.* 12:646240. doi: 10.3389/fphar.2021.646240

In the original article, there were two errors. The Wuhan Central Hospital's animal experiment center was not involved in providing the animals nor in approving experimental procedures, but rather the animal experiment center of Tongji Medical College, Huazhong University of Science and Technology.

A correction has been made to **Materials and Methods**, "Animals," paragraph 1. The corrected paragraph appears below:

"Male C57BL/6 mice (8- to 10-week-old) were supplied by the animal experiment center of Tongji Medical College, Huazhong University of Science and Technology. Mice were allowed 1 week to acclimatize to a stable environment before experiments began. Mice were individually housed in plastic cages with bedding, ad libitum food, and tap water. The cages were maintained at a temperature of $22 \pm 2^\circ\text{C}$ and a 12:12 h light/dark cycle. Mice were randomly assigned to four groups: sham with vehicle (sham-vehicle), sham with RES (sham-RES), HFpEF with vehicle (HFpEF-vehicle), and HFpEF with RES (HFpEFRES). All mice underwent uninephrectomy and received a continuous infusion of either saline (sham) or d-aldosterone (0.15 mg/h) (HFpEF) for 4 weeks via osmotic mini-pumps (Alzet, Durect Corp., Cupertino, CA, United States) (Tanaka et al., 2014). Twenty-4 hours after the surgery, mice were administered RES (10 mg/kg/day) by oral gavage for the duration of 4 weeks (Gupta et al., 2014) (Figure 1B). All experimental procedures were according to the Guidelines for the Care and Use of Laboratory Animals published by the United States National Institutes of Health and were approved by the Animal Care and Use Committee of Tongji Medical College, Huazhong University of Science and Technology (Approval Number: 20191808)."

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Chen, Yan, He, Xie and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

OPEN ACCESS

Edited and reviewed by:

Chrishan S. Samuel,
Monash University, Australia

*Correspondence:

Manhua Chen
chenmh0918@163.com

Specialty section:

This article was submitted to
Cardiovascular and Smooth Muscle
Pharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 18 January 2022

Accepted: 22 February 2022

Published: 18 March 2022

Citation:

Zhang L, Chen J, Yan L, He Q, Xie H
and Chen M (2022) Corrigendum:
Resveratrol Ameliorates Cardiac
Remodeling in a Murine Model of Heart
Failure With Preserved
Ejection Fraction.
Front. Pharmacol. 13:857367.
doi: 10.3389/fphar.2022.857367